Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis by unknown
RESEARCH Open Access
Discrepancy between short-term and long-
term effects of bone marrow-derived cell
therapy in acute myocardial infarction:
a systematic review and meta-analysis
Seon Heui Lee1, Jin Hyuk Hong2, Kyoung Hee Cho3, Jin-Won Noh4* and Hyun-Jai Cho5*
Abstract
Background: Bone marrow-derived cell therapy has been used to treat acute myocardial infarction. However,
the therapeutic efficacy of this approach remains controversial. Here, we performed a systematic review and
meta-analysis to evaluate short-term and long-term effectiveness of bone marrow-derived therapy.
Methods: We searched eight databases (Ovid-Medline, Ovid-EMBASE, Cochrane Library, KoreaMed, KMBASE,
KISS, RISS, and KisTi) up to December 2014. Demographic characteristics, clinical outcomes, and adverse events
were analyzed. We identified 5534 potentially relevant studies; 405 were subjected to a full-text review. Forty-three
studies with 2635 patients were included in this review.
Results: No safety issues related to cell injection were reported during follow-up. At 6 months, cell-injected patients
showed modest improvements in left ventricular ejection fraction (LVEF) compared with the control group. However,
there were no differences between groups at other time points. In the cardiac MRI analysis, there were no significant
differences in infarct size reduction between groups. Interestingly, mortality tended to be reduced at the 3-year
follow-up, and at the 5-year follow-up, cell injection significantly decreased all-cause mortality.
Conclusions: This meta-analysis demonstrated discrepancies between short-term LV functional improvement and
long-term all-cause mortality. Future clinical trials should include long-term follow-up outcomes to validate the
therapeutic efficacy of cell therapy.
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Background
Despite advances in medical therapy and coronary revas-
cularization treatment, ischemic heart disease remains a
major cause of morbidity and mortality worldwide.
Investigation of the new therapies to improve cardiac
function and clinical outcomes after acute myocardial
infarction (AMI) is actively ongoing. Bone marrow
(BM)-derived cell therapy has been investigated experi-
mentally in the context of regenerating or repairing the
damaged heart and vessels [1, 2], and since 2001 [3–5],
more than 100 cell therapy trials, mainly using bone
marrow mononuclear cells (BM-MNCs), have been per-
formed in patients with AMI, establishing the safety and
clinical feasibility of this cell therapy. However, individ-
ual studies are not sufficiently powered to detect any
significant differences in major adverse clinical events
between the cell therapy and control groups. Therefore,
meta-analyses could address the weaknesses of each
study and may provide insights into the clinical out-
comes and benefits of cell therapy.
Most trials have enrolled small numbers of patients
and reported short-term follow-up results, leading to in-
conclusive and inconsistent results in the detection of
significant differences in major adverse clinical events
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between the cell therapy and control groups. To over-
come the limitations of individual studies and increase
statistical power, several meta-analyses have been per-
formed. A meta-analysis in 2012 showed that intracor-
onary BM cell therapy after AMI significantly
improved the left ventricular ejection fraction (LVEF)
at 6 months after treatment; however, the absolute
value of improvement was modest (2.87 %) [6]. In con-
trast, a meta- analysis in 2014 reported that there was
no detectable therapeutic benefit with regard to major
adverse cardiac event rates after BM cell therapy after
a median follow-up duration of 6 months [7], and a
recent meta-analysis in 2015, using individual patient
data from 12 randomized trials, demonstrated no
benefit for 1-year follow-up LVEF and clinical out-
comes [8]. Taken together, these studies suggest that
there could be a discrepancy between the improve-
ment of LV function and clinical outcomes. Further-
more, long-term follow-up results are lacking.
Accordingly, we conducted the largest meta-analysis of
this topic reported to date, including 43 randomized trials
with 2635 patients, and focused on follow-up results at
6 months, 1 year, 3 years, and 5 years in order to evaluate
short-term and long-term effects of the cell therapy in
patients with AMI. We found the significant difference
between cardiac magnetic resonance imaging (MRI)
and echocardiographic measurements of LV functional
improvement and infarction size reduction. Further-
more, we revealed the discrepancy between the LV
function and clinical outcomes. Cell therapy showed
the long-term mortality benefits at 5-year follow-up,
although the effects of LV functional improvement and
infarct size reduction were modest in short-term analyses.
Methods
Information sources and search strategy
We searched eight databases (Ovid-Medline, Ovid-
EMBASE, Cochrane Library, KoreaMed, KMBASE,
KISS, RISS, and KisTi) up to December 2014. To
ensure a sensitive search, we designed strategies that
included medical subject headings (MeSH) keywords,
such as “myocardial infarction”, “acute MI”, “MI”,
“STEMI”, “coronary heart disease”, “angina”, “ischemic
heart disease”, “ischemic cardiomyopathy”, “heart fail-
ure”, “bone marrow cell (BMC)”, “mononuclear cell
(MNC)”, “mesenchymal stem cell”, “mesenchymal
stromal cell”, “MSC”, “granulocyte colony-stimulating
factor (G-CSF)”, and all possible combinations.
Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) randomized
clinical trials (RCTs), (2) published original articles, (3)
written in English, (4) stem cell or cell therapy studies,
and (5) included proper outcomes (follow-up LV function,
mortality, etc.). The exclusion criteria were as follows:
(1) nonhuman studies, (2) preclinical studies, (3) gray
literature, (4) non-RCTs, and (5) duplicated reports.
Two reviewers screened studies according to the selec-
tion criteria. First, we removed duplicate studies and
performed title and abstract screening. Second, we se-
lected potentially pertinent studies and reviewed the
full text. Finally, we chose 43 randomized clinical trials
and analyzed 2635 patients [9–51] (Fig. 1).
Data extraction and quality assessment
Two independent reviewers assessed studies using a
standardized form. Information extracted from the
chosen studies included authors, publication year,
country, design, results, and funding. Clinical outcomes
consisted of complications such as arrhythmia, heart
failure, ischemic heart disease (IHD) recurrence, re-
stenosis, revascularization, stroke, and all-cause mor-
tality. Effectiveness outcomes were improvement of left
ventricular ejection fraction (LVEF) and reduction of
infarct size at each follow-up point. Assessment of the
quality of articles was made according to the Cochrane
Handbook [52]. Two authors (Lee and Hong) evaluated
all of the studies including methodological quality ac-
cording to the risk of bias for randomized controlled
trials.
Statistical analysis
We conducted the meta-analysis using Review Manager
version 5.3 (Cochrane Collaboration). For dichotomous
and continuous variables, the odds ratios (ORs) and
weighted mean differences were calculated for groups
using a random effects model and inverse variance
weighting. Inverse variance weighting is a method of ag-
gregating two or more random variables to minimize the
variance of the weighted average [53]. For studies that
did not report the actual change as the mean, the stand-
ard deviation was calculated using a standardized for-
mula that was previously validated when the baseline
and follow-up standard deviation were known. In this
study, we reported results according to a random
effects model considering heterogeneity, and the publi-
cation bias was tested using a Funnel plot [53, 54]. The
Chi-square test with significance set at P < 0.10 was
used to assess statistical heterogeneity of selected stud-
ies, and I2 statistics were provided to quantify the
heterogeneity.
Results
Search and selection of BM-derived cell therapy
clinical trials
We identified 5534 potentially relevant studies and fur-
ther screened these studies for eligibility. We selected
405 pertinent cell therapy studies for a full-text review.
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The outcomes of interest included demographic char-
acteristics, clinical outcomes, and effectiveness out-
comes at each follow-up point. Of these 405 studies,
362 were excluded because they were not describing
acute MI (n = 39), were not RCTs (n = 122), were gray
literature (n = 1), were duplicate reports (n = 50), did
not include clinical outcomes (n = 136), were not
interventional studies (n = 10), and were not MI stud-
ies (n = 3). We finally included 43 studies with 2635
patients [9–51] (Fig. 1).
Study characteristics
The studies were published from 2004 to 2014. Table 1
lists the characteristics all of the included studies. The
study sizes ranged from 8 to 204 patients, and the
follow-up duration ranged from 3 to 108 months.
Twenty-four of 41 studies were conducted in Europe, six
studies were conducted in the USA, five studies were
conducted in China, three studies were conducted in
Korea, one study was conducted in Mexico, one study
was conducted in Canada, one study was conducted in
Thailand, one study was conducted in Brazil, and one
study was conducted in Iran. Among the 2635 patients,
1399 patients received BM-derived cell therapy, and
1236 patients were in the control group. Most studies
used freshly isolated BM-MNCs isolated by density gra-
dient separation of autologous BM aspirates. Three
studies used BM-derived CD133+ cells by cell sorting
using a specific antibody [20, 28, 30], and one study used
CD34+ cells [24]. Two studies used granulocyte colony-
stimulating factor (G-CSF)-mobilized peripheral blood
mononuclear cells (PB-MNCs) by leukapheresis [17, 50],
and two other studies used mesenchymal stem cells
(MSCs), which were cultured from BM aspirates under
attached conditions for 1 month [11, 35]. Most cell in-
jections were performed through intracoronary infusion
2 to 7 days after percutaneous coronary intervention
(PCI). One study infused cells intravenously after PCI
[35] and another study injected cells intramuscularly
through the epicardium during coronary artery bypass
graft operation [28]. The total number of injected cells is
listed in Table 1.
Functional improvement of the LV and reduction of
infarct size
Analyses based on a random effects model for the differ-
ence in LVEF and infarct size are shown in Fig. 2. Cell
therapy improved the LVEF at 6 months (2.75 % in-
crease; P < 0.001) and 1 year (1.34 % increase; P = 0.03)
as compared with the control group (Fig. 2a and b).
However, at the 3- and 5-year follow-up, there were no
significant differences in LVEF between the cell therapy
and control groups (Fig. 2c and d). Infarct size in the cell
therapy tended to decrease at 6 months compared with
Fig. 1 Flow diagram of the literature selection process and meta-analysis
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Table 1 Study characteristics








Cell type Cell delivery
route




Assmus et al. [9] 2014 Germany After PCI 101 103 204 MNC IC Ficoll gradient 1 × 106 60
Benedek et al. [10] 2014 Romania After PCI 9 9 18 MNC IC Concentration by
apheresis
1.66 ± 0.32 × 109 48
Lee et al. [11] 2014 Korea After PCI 30 28 58 MSC IC 1-month culture 7.2 ± 0.90 × 107 6
Robbers et al. [12] 2014 Netherlands After PCI 30 45 75 BM-MNC/PB-
MNC
IC Lymphoprep™ 296 ± 164 × 106 4
Gao et al. [13] 2013 China After PCI 21 22 43 MSC IC 2-week culture 3.08 ± 0.52 x 106 6, 12, 24
Surder et al. [14] 2013 Switzerland After PCI 65 67 132 MNC IC Density gradient 5 × 107 - 5 × 108 4
Wohrle et al. [15] 2013 Germany After PCI 29 13 42 MNC IC Ficoll gradient 324 × 106 6, 12, 24,
36
Jazi et al. [16] 2012 Iran After PCI 16 16 32 MNC IC Ficoll gradient 24.6 ± 8.4 × 108 6
Kang et al. [17] 2012 Korea After PCI 57 60 117 PB-MNC IC G-CSF/leukapheresis 1.1 ± 0.5 × 109 6, 24, 60
Skalicka et al. [18] 2012 Czech After PCI 17 10 27 MNC IC Gelfusine 26.4 × 108 4, 24
Traverse et al. [19] 2012 USA After PCI 79 41 120 MNC IC Sepax® 150 × 106 6
Colombo et al. [20] 2011 Italy After PCI 5 5 10 CD133+ MNC IC CD133 by CliniMACS® 4.9-135 × 106 12
Hirsch et al. [21] 2011 Netherlands After PCI 69 65 134 MNC IC Lymphoprep™ 296 ± 164 × 106 4
Pena-Duque et al. [22] 2011 Mexico After PCI 4 4 8 MNC IC Sepax® 1 ~ 2 × 106 CD34
+
6
Plewka et al. [23] 2011 Poland After PCI 40 20 60 MNC IC Safe Flow® 1.44 ± 0.49 × 108 24
Quyyumi et al. [24] 2011 USA After PCI 16 15 31 CD34+ MNC IC Isolex 300i® 5 × 106 6, 12
Roncalli et al. [25] 2011 France After PCI 52 49 101 MNC IC Ficoll 98 ± 8.7 × 106 3
Srimahachota et al.
[26]
2011 Thailand After PCI 11 12 23 MNC IC Isoprep® 420 ± 221 × 106 6
Turan et al. [27] 2011 Germany After PCI 38 18 56 MNC IC Point of Care system 1 × 106 3, 12
Yerebakan et al. [28] 2011 Germany During
CABG
20 20 40 CD133+ MNC IM CD133 by CliniMACS® 6.0 × 106 108
Grajek et al. [29] 2010 Poland After PCI 31 14 45 MNC IC Ficoll gradient 4.1 ± 1.8 × 108 3, 6, 12
Mansour et al. [30] 2010 Canada After PCI 14 14 CD133+ MNC IC CliniMACS® 10 × 106- 4
Piepoli et al. [31] 2010 Italy After PCI 19 19 38 MNC IC Ficoll gradient 418 × 106 3, 6, 12
Traverse et al. [32] 2010 USA After PCI 30 10 40 MNC IC Ficoll gradient 100 × 106 6
Wohrle et al. [33] 2010 Germany After PCI 29 13 42 MNC IC Ficoll gradient 381 ± 130 × 106 6
Cao et al. [34] 2009 USA After PCI 41 45 86 MNC IC Lymphoprep™ 5 ± 1.2 × 107 48
Hare et al. [35] 2009 USA After PCI 39 21 60 MSC (allogeneic) IV 1-month culture 0.5 ~ 5 × 106 6












Table 1 Study characteristics (Continued)
Yao et al. [37] 2009 China After PCI 12 12 24 MNC IC Ficoll gradient 1.9 ± 1.3 × 108 6, 12
Huikuri et al. [38] 2008 Finland After PCI 40 40 80 MNC IC Ficoll gradient 4.02 ± 1.96 × 106 6
Meluzin et al. [39] 2008 Czech After PCI 20 20 40 MNC IC Histopaque1077 1-10 × 107 3, 6, 12
Panovsky et al. [40] 2008 Czech After PCI 13 17 30 MNC IC Histopaque1077 1-10 × 108 3
de Lezo et al. [41] 2007 Spain After PCI 10 10 20 MNC IC Ficoll gradient 9 ± 3 × 108 3
Ge et al. [42] 2006 China After PCI 10 10 20 MNC IC Ficoll gradient 4 × 107 6
Janssens et al. [43] 2006 Belgium After PCI 33 34 67 MNC IC Ficoll gradient 172 ± 72 × 106 4
Lunde et al. [44] 2006 Norway After PCI 47 50 97 MNC IC Ficoll gradient 68 × 106 6, 36
Meluzin et al. [45] 2006 Czech After PCI 22 22 44 MNC IC Histopaque1077 1x107 -1 × 108 3
Schachinger et al. [46] 2006 Germany After PCI 101 103 204 MNC IC Ficoll gradient 236 ± 174 × 106 24
Karpov et al. [47] 2005 Russia After PCI 22 22 44 MNC IC Histopaque1077 88.5 ± 49.2 × 106 6
Ruan et al. [48] 2005 China After PCI 9 11 20 MNC IC Not described Not described 6
Chen et al. [49] 2004 China After PCI 34 35 69 MSC IC 10-day culture 2-5 × 106 3, 6
Kang et al. [50] 2004 Korea After PCI 6 7 13 PB-MNC IC G-CSF/leukapheresis 1 × 109 6, 24
Wollert et al. [51] 2004 Germany After PCI 30 30 60 MNC IC 4 % gelatine-
polysuccinate
24.6 ± 9.4 × 108 6, 18, 60
Included studies were all randomized clinical trials (RCTs). Plus-minus value indicates mean ± SE
PCI percutaneous coronary intervention, MNC mononuclear cell, IC intracoronary cell infusion, BM-MNC bone marrow-derived mononuclear cell, PB-MNC peripheral blood-derived mononuclear cell, G-CSF granulocyte












Fig. 2 (See legend on next page.)
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that in the control group; however, this difference was not
statistically significant (−2.99 %; 95 % confidence interval
[CI],−7.08, 1.11; P = 0.15; Fig. 3a). At the 1-year follow-up,
infarct size was significantly reduced (−6.10 %; 95 % CI,
−11.14, −1.05; P = 0.02; Fig. 3b). However, there were no
significant differences in infarct size at the 3-year (1.10 %;
95 % CI, −9.24, 11.44; P = 0.83; Fig. 3c) and 5-year follow-
up (1.10 %; 95 % CI, −9.24, 11.44; P = 0.83; Fig. 3d).
Taken together, these data indicated that the differ-
ences in LV systolic function and infarct size between
the cell therapy and standard care control groups disap-
peared within 1 year of the initial treatment.
Difference between measurement modalities
It is possible for there to be differences in measurements
between the modalities [12]. Accordingly, we performed
subgroup analysis of the results from cardiac MRI and
echocardiography (or LV angiogram). LVEF measured by
cardiac MRI showed no significant difference between
the cell therapy and control groups (0.51 %; 95 % CI,
−1.20, 2.23; P = 0.56), whereas echocardiographic (or LV
angiographic) measurement (non-MRI) revealed that cell
therapy significantly increased LVEF compared with
that in the control group (4.02 %; 95 % CI, 2.65, 5.39;
P < 0.001; Table 2 and Fig. 4a).
To examine the effects of study design on maintaining
blindness, we also analyzed bone marrow aspiration and
placebo infusion in patients in the control group. Pa-
tients were separated into two groups according to
whether each procedure was used in the control group;
cells were isolated from the BM by aspiration and in-
fused placebo in the control group (placebo procedure),
or no procedure was performed in the control group
(Table 2). The outcome was measured as the change in
LVEF from baseline to 6 months. Significant effects were
observed the group in which the control group underwent
aspiration and placebo infusion, as indicated by an LVEF
of 1.86 % (95 % CI, 0.54, 3.19; P = 0.006). Additionally, the
other group in which no procedures were performed
showed significant differences in LVEF (3.20 %; 95 % CI,
1.84, 4.56; P < 0.001).
Regarding the reduction in infarct size (Table 2 and
Fig. 4b), MRI measurement did not show any significant
differences in infarct size (−3.96 %; 95 % CI, −10.81, 2.90;
P = 0.26) between the cell therapy and control groups.
Moreover, non-MRI modalities (echocardiography or LV
angiogram) also showed no significant differences (0.1 %;
95 % CI, −0.09, 0.29; P = 0.29). No significant treatment
effect was found the group in which the control group
underwent aspiration in infarct size (−7.93 %; 95 % CI,
−19.57, 3.72; P = 0.18). Additionally, lack of aspiration
in the control group did not have any beneficial effects
on infarct size reduction (0.55 %; 95 % CI, −0.62, 1.72;
P = 0.36).
Major adverse clinical events
The safety of BM cell harvesting and delivery has been
established. All-cause mortality was analyzed by the
Mantel-Haenszel (M-H) random model, which is one of
the most popular procedures for detecting differential
item functioning [55]. If we assume a constant relative
Odds (θi = μ or Δ
2 = 0), then the Mantel-Haenszel statis-
tic is optimal for testing H0 : μ = 1, and there is consider-
able literature on efficient estimates of μ and on
methods for testing H0 : θ1 = θ2 =… = θk [56].
The results demonstrated that there were no differ-
ences between groups at the 6-month (odds ratio [OR],
1.08; 95 % CI, 0.42, 2.8; P = 0.87) and 1-year follow-up
(OR, 0.89; 95 % CI, 0.24, 3.32; P = 0.86; Table 3 and
Fig. 5). Interestingly, mortality tended to decrease at the
3-year follow-up in the cell therapy group compared
with that in the control group (OR, 0.58; 95 % CI, 0.22,
1.56; P = 0.28). At 5 years, 458 patients were followed up
from five studies. BM-derived cell therapy significantly
decreased all-cause mortality, with a 55 % relative risk
reduction (OR, 0.45; 95 % CI, 0.21, 0.97; P = 0.04). All-
cause mortality occurred in 4.4 % (10 deaths in 226 pa-
tients) in the cell therapy group and 9.5 % (22 deaths in
232 patients) in the control group.
In the morbidity analysis, including heart failure,
recurrence of IHD, repeated revascularization, and
stroke (Table 3), the cell therapy group generally showed
favorable outcomes; however, this difference was not sta-
tistically significant compared with the control.
Taken together, these data indicated that BM-derived
cell therapy for patients with AMI produce clinical bene-
fits in the long-term follow-up.
Discussion
Here, we conducted a systematic review and meta-
analysis of comparative studies to evaluate effectiveness
of BM-derived cell therapy for patients with AMI. Our
study included the greatest number of publications de-
scribing cell therapy trials to date and reflects the latest
clinical outcomes and long-term follow-up results. We
included all types of BM-derived cell therapy trials and
(See figure on previous page.)
Fig. 2 Improvement of left ventricular function. Forest plot and meta-analysis of the left ventricular ejection fraction (LVEF) at the 6-month, 1-year,
3-year, and 5-year follow-up. The weighted mean differences were calculated for groups using a random effects model and inverse variance
weighting. Inverse variance weighting is a method for aggregating two or more random variables to minimize the variance of the weighted
average. a LVEF at 6 months after treatment. b LVEF at 1 year. c LVEF at 3 years. d LVEF at 5 years
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Fig. 3 Infarct size reduction. Forest plot and meta-analysis of infarct size at the 6-month, 1-year, 3-year, and 5-year follow-up. a Infarct size at
6 months after treatment. b Infarct size at 1 year. c Infarct size at 3 years. d Infarct size at 5 years
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analyzed 2635 patients. Among 43 studies, the majority
of trials used uncultured fresh autologous BM aspirates
and applied a density gradient to separate MNCs. Two
trials employed G-CSF-mobilized peripheral blood
MNCs, and four trials utilized CD133+ or CD34+ BM-
MNCs separated by antibody-based cell sorting. Two tri-
als cultured BM aspirates for 1 month to obtain MSCs.
In terms of cell delivery, most studied applied intracor-
onary infusion through the balloon catheter.
Although the feasibility of cell therapy has been dem-
onstrated in clinical trials, safety should be considered as
a priority in future clinical studies. Malignant tumor for-
mation after transplantation of BM MSCs into animal
hearts suggests that the unstable chromosomal status of
cultured cells could induce serious adverse events [57].
Furthermore, the calcifying activity of uncultured BM
cells has also been reported in preclinical animal studies
[58]. These data suggest that careful monitoring of cells
before transplantation and long-term follow-up for
safety should be performed in clinical trials.
The individual studies were not sufficiently powered
to detect significant differences in major adverse clin-
ical events between the cell therapy and control group.
Therefore, meta-analyses can be used to evaluate ap-
propriate results of each study and may provide in-
sights into clinical outcomes and benefits of cell
therapy. In this meta-analysis, we focused on follow-up
results at 6 months, 1 year, 3 years, and 5 years in
order to evaluate short-term and long-term effects of
the cell therapy. We found that at 6 months, the cell-
injected group showed a modest or insignificant im-
provement in LVEF, depending on the measurement
modality. However, there was a tendency toward de-
creased mortality at 3 years. At the 5-year follow-up,
cell injection significantly decreased all-cause mortality
(55 % relative risk reduction) as compared with that in
the control group, indicating a discrepancy between
the short-term LV functional improvement and long-
term all-cause mortality.
We further reviewed the specific mode of death of all-
cause mortality. The REPAIR-AMI study at the 5-year
follow-up demonstrated that BM-derived cell therapy
tended to reduce cardiac death (4 deaths/100 patients)
compared with that of the placebo treatment (14 deaths/
100 patients) [9]. Additionally, the MAGIC-Cell study at
the 5-year follow-up showed that G-CSF-mobilized cell
therapy decreased cardiac death (no deaths/57 patients)
compared with that of the control treatment (2 deaths/
60 patients) [17]. These data suggested that the effects
of cell therapy on mortality could be primarily driven by
the reduction of cardiac death after MI.
Functional improvement of LV systolic function was
modest, as compared to the standard care of revasculari-
zation and medical treatment of MI, BM-derived cell
therapy showed better clinical outcomes and survival
benefits in the long-term follow-up analysis. We would
like to suggest several putative explanations for the
significant clinical benefit after cell therapy. First, LV
functional improvement and infarct size reduction at the
early phase after revascularization with cell therapy
could affect long-term outcomes according to the “leg-
acy effect”, which was described in a prior diabetes trial;
the difference in glycosylated hemoglobin (HbA1c) levels
between intensively and conventionally treated pa-
tients disappeared within 1 year of the completion of
the trial. Nevertheless, outcomes continued to favor
the intensively treated group [59]. This meta-analysis
suggests that LVEF at short-term follow-up after cell
therapy could affect long-term cardiovascular out-
comes. REPAIR-AMI long-term follow-up at 2 and
Table 2 Subgroup analysis of left ventricular ejection fraction and infarct size at 6 months
Outcome Subgroup Studies Cell-injected group Control group Mean difference I2 (%)
participants (n) participants (n) IV, random (%) 95 % CI
LVEF Group 1 MRI 11 358 243 0.51 −1.20, 2.23 74
Echo or LV angiogram 14 310 283 4.02 2.65, 5.39 94
Total 25 668 526 2.65 1.61, 3.69 92
Group 2 Placebo procedure 9 296 195 1.86 0.54, 3.19 64
No procedure 15 358 325 3.20 1.83, 4.56 94
Total 24 654 520 2.63 1.59, 3.67 92
Infarct size Group 1 MRI 5 187 116 −3.96 −10.81, 2.90 96
Echo or LV angiogram 1 20 20 0.10 −0.09, 0.29 NA
Total 6 207 136 −3.09 −7.19, 1.02 95
Group 2 Placebo procedure 3 133 63 −7.93 −19.57, 3.72 97
No procedure 3 74 73 0.55 −0.62, 1.72 31
Total 6 207 136 −3.09 −7.19, 1.02 95
IV inverse variance, CI confidence interval, I2 inconsistency (across studies), MRI magnetic resonance imaging, LVEF left ventricular ejection fraction
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5 years demonstrated favorable clinical outcomes, in-
cluding cardiovascular death and rehospitalization for
heart failure. Specifically, lower LVEF and increased LV
end systolic volume at 4 months were associated with
adverse long-term outcomes [9, 60]. These data indi-
cated that the functional improvement of LV at the
early stage after cell transplantation would induce long-
term benefits, although there was no significant difference
in LVEF at long-term follow-up. Furthermore, to over-
come such limitations of a single cell transplantation pro-
cedure and to achieve better outcomes, repeated cell
transplantation is currently under investigation [61]. Sec-
ond, there is a possibility of sustained LV functional
improvement with a small degree after cell therapy.
Although this meta-analysis showed no significant differ-
ences in LV function and infarct size at the 3- and 5-year
follow-up between the cell therapy and control groups, a
previous report suggested that the improvement in LVEF
may be maintained over a long-term follow-up of 1–5
years [6]. Third, microvascular improvement thorough en-
hanced angiogenesis and cardioprotective effects could be
contributed to outcomes. However, an MRI study re-
ported that cell therapy did not augment the perfusion of
the ischemic myocardium [12]. Fourth, patients with
recovered LV function after standard revascularization
therapy, considered as a low-risk population, could dilute
Fig. 4 Left ventricular function and infarct size measured by cardiac MRI versus echocardiography or LV angiogram (non-MRI). a LVEF at the end
point. b Infarct size at the end point
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benefits of cell therapy. In the REPAIR-AMI trial, patients
with an LVEF below 48 % after the primary PCI showed
LV functional improvement after cell infusion [62]. There
was no difference between the cell therapy and control
group in patients with LVEF above 48 %. In addition,
CD133+ BM-derived cell therapy during coronary artery
bypass grafting (CABG) demonstrated that patients with a
pre-operative LVEF of less than 40 % gained more LV
functional improvement after cell therapy as compared
with that in patients with LVEF higher than 40 % [28].
Taken together, these data suggested that patients with
greater damage from AMI could receive greater benefits
from BM-derived cell therapy.
More than a decade after the initial cell therapy trial
for MI, even though considerable knowledge has been
accumulated, there are still many challenges to achieving
favorable clinical outcomes [63]. The inconsistent clin-
ical results of autologous BM cells may be due to the
considerable patient-to-patient variability related to a
decrease in the number and potency of stem and pro-
genitor cells. These discrepancies may also be caused by
the limitations of functional LV measurement. Although
cardiac MRI is considered the gold standard for meas-
urement of the LVEF, volumes and infarct size, it is diffi-
cult to distinguish the infarct from myocardia edema
using MRI. Moreover, the cell processing strategy is also
a controversial factor that may yield inconsistent clinical
results.
The mechanisms mediating the benefits of cell injec-
tion remain unclear. In molecular and cellular analyses
of BM-derived cell therapy, recent accumulating data
have revealed the limited therapeutic efficacy of this
strategy. Although BM cells have shown cardiovascular
differentiation after transplantation into infarcted hearts,
transdifferentiation is considered a rare event [64]. In
vivo cell tracking studies in patients using FDG-PET
have demonstrated that less than 1 % of delivered cells
stay in the myocardium after 24 hours of cell injection,
indicating poor engraftment [65]. Therefore, paracrine
effects of injected BM cells via the release of several
humoral factors have also been proposed as the main
mechanism of action [66]. However, autologous cells
from diseased and elderly patients impair cellular func-
tion for regeneration and repair of infarcted hearts. To
overcome such limitations, clinical trials investigating
resident cardiac progenitor cell-based therapy and allo-
geneic healthy donor-derived cell therapy as well as
repeated cell administration are ongoing to determine
the merits of these second-generation cell therapies.
Limitations
This study has several limitations. First, pooled data for
the meta-analysis showed different baseline characteris-
tics between the cell therapy and placebo groups, which
likely reduces the comparability of the meta-analysis.
Furthermore, according to the specific study protocol of
Table 3 Major adverse events
Event Cell therapy group Control group Odds ratio
Follow-up Study (participants) Total event Participants Total event Participants (M-H, random) 95 % CI
All-cause mortality 6 mo 18 (1284) 10 707 6 577 1.08 0.42–2.81
1 yr 8 (286) 5 174 4 112 0.89 0.24–3.32
3 yr 5 (432) 9 228 11 204 0.58 0/22–1.56
5 yr 5 (458) 10 226 22 232 0.45 0.21–0.97
Heart failure admission 6 mo 9 (970) 10 512 15 458 0.56 0.24–1.31
1 yr 3 (83) 2 42 0 41 3.07 0.30–30.96
2 yr 4 (333) 4 179 14 154 0.15 0.04–0.50
3 yr 6 (577) 11 284 17 293 0.65 0.30–1.44
Recurrence of ischemic
heart disease
6 mo 14 (1214) 29 663 37 551 0.57 0.32–1.00
1 yr 2 (81) 0 48 1 33 0.14 0.01–3.68
2 yr 6 (373) 6 199 11 174 0.68 0.18–2.56
3 yr 6 (528) 9 262 11 266 0.81 0.33–2.00
Revascularization/restenosis 6 mo 14 (1212) 98 662 92 550 0.87 0.63–1.22
1 yr 4 (156) 2 87 4 69 0.37 0.07–1.89
2 yr 6 (373) 36 199 45 174 0.65 0.39–1.10
3 yr 6 (577) 62 284 76 293 0.77 0.52–1.15
Cerebral vascular accident (CVA) 1 yr 2 (150) 1 68 2 82 0.69 0.08–5.81
2 yr 3 (500) 5 248 10 252 0.5 0.16–1.50
M-H Mantel-Haenszel, CI confidence interval, mo months, yr years
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Fig. 5 Forest plot and meta-analysis of all-cause mortality. a All-cause mortality at 6 months after treatment. b All-cause mortality at the 1-year
follow-up. c All-cause mortality at the 3-year follow-up. d All-cause mortality at the 5-year follow-up
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each study, there were several differences in procedures
for cell harvesting, separation, mode of delivery, and
timing of delivery. Second, the number of clinical events
was small during the follow-up period, although patients
suffered from AMI. In 5 years after enrollment, a total
of 32 deaths occurred in 458 patients (4.4 % mortality
rate in the cell therapy group and 9.5 % mortality rate in
the control group). This low event rate could be ex-
plained by the exclusion of high-risk patients in most
trials, such as those with severe LV dysfunction and
heart failure after large myocardial infarction. Clinical
events in heart failure patients who were hospitalized
due to decompensation have been reported to be
approximately 6 % for in-hospital deaths, and even in
patients who were discharged alive, the 6-month all-
cause mortality rate was 10 % [67]. Accordingly, cell
therapy trials for high-risk patients with AMI should be
performed to clearly address the clinical benefits of the
new therapeutic modality.
Conclusions
We conducted a meta-analysis of BM-derived cell ther-
apy for patients with AMI and showed that this therapy
was associated with long-term mortality benefits, al-
though the effects of LV functional improvement and in-
farct size reduction were modest in short-term analyses.
In this regard, to validate the therapeutic efficacy of cell
therapy, future randomized clinical trials should include
sufficient sample sizes with greater power to detect
long-term clinical outcomes rather than surrogate short-
term hemodynamic and image-based variables.
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